119 related articles for article (PubMed ID: 11841411)
1. Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia.
Marley SB; Davidson RJ; Goldman JM; Gordon MY
Br J Haematol; 2002 Jan; 116(1):162-5. PubMed ID: 11841411
[TBL] [Abstract][Full Text] [Related]
2. Phosphatidylinositol-3 kinase inhibitors reproduce the selective antiproliferative effects of imatinib on chronic myeloid leukaemia progenitor cells.
Marley SB; Lewis JL; Schneider H; Rudd CE; Gordon MY
Br J Haematol; 2004 May; 125(4):500-11. PubMed ID: 15142121
[TBL] [Abstract][Full Text] [Related]
3. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
Scappini B; Onida F; Kantarjian HM; Dong L; Verstovsek S; Keating MJ; Beran M
Cancer; 2002 May; 94(10):2653-62. PubMed ID: 12173333
[TBL] [Abstract][Full Text] [Related]
4. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Hoover RR; Mahon FX; Melo JV; Daley GQ
Blood; 2002 Aug; 100(3):1068-71. PubMed ID: 12130526
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Thiesing JT; Ohno-Jones S; Kolibaba KS; Druker BJ
Blood; 2000 Nov; 96(9):3195-9. PubMed ID: 11050003
[TBL] [Abstract][Full Text] [Related]
6. The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Korycka A; Robak T
Leuk Lymphoma; 2003 Sep; 44(9):1549-55. PubMed ID: 14565659
[TBL] [Abstract][Full Text] [Related]
7. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
O'Dwyer M
Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
[TBL] [Abstract][Full Text] [Related]
8. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents.
Liu WM; Stimson LA; Joel SP
Br J Cancer; 2002 May; 86(9):1472-8. PubMed ID: 11986783
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alfa-based treatment of chronic myeloid leukemia and implications of signal transduction inhibition.
Talpaz M
Semin Hematol; 2001 Jul; 38(3 Suppl 8):22-7. PubMed ID: 11526598
[TBL] [Abstract][Full Text] [Related]
10. Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo.
Marley SB; Davidson RJ; Lewis JL; Nguyen DX; Eades A; Parker S; Goldman JM; Gordon MY
Leuk Res; 2001 Nov; 25(11):997-1002. PubMed ID: 11597734
[TBL] [Abstract][Full Text] [Related]
11. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
Nakajima M; Toga W
Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
[TBL] [Abstract][Full Text] [Related]
12. [Drug therapy of chronic myeloid leukemia].
Hochhaus A; Berger U; Reiter A; Lahaye T; Kreil S; Hehlmann R
Med Klin (Munich); 2002 Jan; 97 Suppl 1():7-15. PubMed ID: 11831070
[TBL] [Abstract][Full Text] [Related]
13. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
Buchdunger E
Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
[TBL] [Abstract][Full Text] [Related]
14. Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM.
Marley SB; Davidson RJ; Goldman JM; Gordon MY
Leukemia; 2000 Aug; 14(8):1396-400. PubMed ID: 10942234
[TBL] [Abstract][Full Text] [Related]
15. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
16. [How I treat...chronic myeloid leukemia].
Hafraoui K; Humblet-Baron S; Baron F; Beguin Y; Fillet G
Rev Med Liege; 2003 Jan; 58(1):7-12. PubMed ID: 12647591
[TBL] [Abstract][Full Text] [Related]
17. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
18. Low concentrations of STI571 in the cerebrospinal fluid: a case report.
Petzer AL; Gunsilius E; Hayes M; Stockhammer G; Duba HC; Schneller F; Grünewald K; Poewe W; Gastl G
Br J Haematol; 2002 Jun; 117(3):623-5. PubMed ID: 12028032
[TBL] [Abstract][Full Text] [Related]
19. Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Sacchi S; Kantarjian HM; Freireich EJ; O'Brien S; Cortes J; Rios MB; Kornblau S; Giles FJ; Koller C; Gajewski J; Talpaz M
Leuk Lymphoma; 1999 Nov; 35(5-6):483-9. PubMed ID: 10609785
[TBL] [Abstract][Full Text] [Related]
20. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Gambacorti-Passerini C; Barni R; le Coutre P; Zucchetti M; Cabrita G; Cleris L; Rossi F; Gianazza E; Brueggen J; Cozens R; Pioltelli P; Pogliani E; Corneo G; Formelli F; D'Incalci M
J Natl Cancer Inst; 2000 Oct; 92(20):1641-50. PubMed ID: 11036109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
